OXALIPLATIN

作品数：219被引量：667H指数：13
导出分析报告
相关领域：医药卫生更多>>
相关作者：尹文琤阙琳玲余四旺曹宝山高键更多>>
相关机构：中山大学苏州大学山东大学吉林大学更多>>
相关期刊：更多>>
相关基金：国家自然科学基金广东省自然科学基金上海市自然科学基金国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Oxaliplatin-induced diffuse alveolar hemorrhage:A case report
《World Journal of Clinical Oncology》2025年第4期343-348,共6页Toshiaki Tsurui Emiko Mura Atsushi Horiike Takuya Tsunoda 
BACKGROUND Drug-induced lung injury is a common adverse effect of chemotherapeutic agents.Diffuse alveolar hemorrhage(DAH)is a fatal complication associated with druginduced lung injury.Early diagnosis and treatment o...
关键词：Diffuse alveolar hemorrhage OXALIPLATIN Esophageal neoplasms Lung injury Drug therapy Case report 
Increased keratin 80 expression predicts poor prognosis and promotes oxaliplatin resistance in gastric cancer
《World Journal of Gastroenterology》2025年第12期150-170,共21页Bo Yang Hong-Xia Cao Ya-Wei He Ji-Jie Ouyang Meng Lv Yong-Xiang Li Yi-Da Lu 
Supported by National Natural Science Foundation of China,No.874063.
BACKGROUND Keratin 80(KRT80),a type I intermediate filament protein,is a member of the keratin family with specialized functions in epithelial tissues.While KRT80 has been implicated in both normal physiological proce...
关键词：Keratin 80 Gastric cancer OXALIPLATIN Elongation factor 1-alpha 1 Gastrointestinal tract Signaling pathway 
NAD+/SIRT1 pathway regulates glycolysis to promote oxaliplatin resistance in colorectal cancer
《World Journal of Gastroenterology》2025年第11期118-134,共17页Ya-Ru Niu Mi-Dan Xiang Wen-Wei Yang Yu-Ting Fang Hai-Li Qian Yong-Kun Sun 
Supported by the National Natural Science Foundation of China,No.82072756;Beijing Xisike Clinical Oncology Research Foundation,No.Y-HR2019-0285.
BACKGROUND Glycolysis provides growth advantages and leads to drug resistance in colorectal cancer(CRC)cells.SIRT1,an NAD+-dependent deacetylase,regulates various cellular processes,and its upregulation results in ant...
关键词：Colorectal cancer Chemotherapy resistance GLYCOLYSIS SIRT1 NAD+ 
Efficacy of fluorouracil combined with paclitaxel and oxaliplatin for the treatment of advanced gastric signet ring cell carcinoma
《World Journal of Gastrointestinal Surgery》2025年第3期69-78,共10页Mi Liu Bei Feng Na He Rong Yan Jie Qin 
BACKGROUND Gastric signet ring cell carcinoma(GSRC)is a distinctive type of gastric cancer.It is a mucus-secreting adenocarcinoma that may progress to distant metastasis at an early stage.Because of poor differentiati...
关键词：OXALIPLATIN Tigio Carcinoembryonic antigen Carbohydrate antigen 19-9 Advanced gastric signet ring cell carcinoma 
Effects of Huaier Regulating Oxaliplatin Resistance in Colorectal Cancer through PI3K/AKT Signaling Pathway
《Medicinal Plant》2025年第1期64-69,共6页Luwen WEN Mingyi HUO Yanan YUAN Xin LIU Jining ZHENG 
Supported by the Project Funding of Hebei Provincial Education Department(ZD2020137);the Key Discipline Construction Project of Hebei Provincial Universities[JiJiaoGao-2013-(4)-2012-37].
[Objectives]To investigate whether Huaier(Trametes robiniophila Murr)can reverse oxaliplatin resistance of colorectal cancer and its molecular mechanism.[Methods]CCK8 assays were used to analyze the effect of Huaier o...
关键词：Huaier(Trametes robiniophila Murr) Drug resistance Colorectal cancer PI3K/AKT Apoptosis 
Addition of SHR-1701 to first-line capecitabine and oxaliplatin(XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
《Signal Transduction and Targeted Therapy》2025年第1期340-349,共10页Miao-Zhen Qiu Yuxian Bai Jufeng Wang Kangsheng Gu Mudan Yang Yifu He Cheng Yi Yongdong Jin Bo Liu Feng Wang Yu-kun Chen Wei Dai Yingyi Jiang Chuanpei Huang Rui-Hua Xu Hui-Yan Luo 
supported by Jiangsu Hengrui Pharmaceuticals and the following grants:the National Natural Science Foundation of China(NSFC:82321003,82173128,82073377,81930065);the Natural Science Foundation of Guangdong(2021A1515012439);Guangdong Basic and Applied Basic Research Foundation(2024B1515020120);the CAMS Innovation Fund for Medical Sciences(CIFMS:2019-I2M-5-036);Additional funding was provided by the Cancer Innovative Research Program of Sun Yat-sen University Cancer Center(CIRP-SYSUCC-0004).
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β,in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxal...
关键词：BEVACIZUMAB colorectal SHR 
AKR1C1 interacts with STAT3 to increase intracellular glutathione and confers resistance to oxaliplatin in colorectal cancer
《Acta Pharmaceutica Sinica B》2024年第12期5305-5320,共16页Zhiwen Fu Tingting Wu Chen Gao Lulu Wang Yu Zhang Chen Shi 
supported by the National Natural Science Foundation of China(Grant Nos.82204758 and 82073402).
Oxaliplatin(OXA),a platinum-based chemotherapeutic agent,remains a mainstay in first-line treatments for advanced colorectal cancer(CRC).However,the eventual development of OXA resis-tance represents a significant cli...
关键词：Oxaliplatin resistance AKR1C1 Colorectal cancer ALANTOLACTONE GLUTATHIONE Combination therapy Natural product CHEMORESISTANCE 
Colon-specific controlled release of oral liposomes for enhanced chemo-immunotherapy against colorectal cancer
《Acta Pharmaceutica Sinica B》2024年第11期4977-4993,共17页Mengya Niu Yihan Pei Tiantian Jin Junxiu Li Liming Bai Cuixia Zheng Qingling Song Hongjuan Zhao Yun Zhang Lei Wang 
National Natural Science Foundation of China(Nos.82171333,82272847,82202318);Postdoctoral Fellowship Program of CPSF(GZB20230675,China);The Henan Province Fund for Cultivating Advantageous Disciplines(No.222301420012,China);Central Plains Science and Technology Innovation Leading Talent Project(No.234200510005,China);Graduate Education Reform Project of Henan Province(2023SJGLX127Y,China).
A colon-specific drug delivery system has great potential for the oral administration of colorectal cancer.However,the uncontrollable in vivo fate of liposomes makes their effectiveness for colonic location,and intrat...
关键词：Colorectal cancer Colon-specific delivery Oral liposomes OXALIPLATIN Intratumoral bacteria CHEMO-IMMUNOTHERAPY Clostridium butyricum spores Gut microbiota 
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
《World Journal of Gastroenterology》2024年第40期4367-4375,共9页Ying Kong Qi Dong Peng Jin Ming-Yan Li Li Ma Qi-Jun Yi Yu-E Miao Hai-Yan Liu Jian-Gang Liu 
Supported by China Scientific Research Fund for HER2 Target from China Anti-Cancer Association,No.CORP-239-M9.
BACKGROUND Patients with human epidermal growth factor receptor 2(HER2)-positive advanced gastric cancer have poor outcomes.Trastuzumab combined with chemotherapy is the first-line standard treatment for HER2-positive...
关键词：Human epidermal growth factor receptor 2-positive Advanced gastric cancer Inetetamab TRASTUZUMAB EFFICACY Safety 
Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs.capecitabine for pathological stage N2 rectal cancer
《Chinese Journal of Cancer Research》2024年第5期577-586,共10页Ning Li Yuan Zhu Luying Liu Yanru Feng Wenling Wang Jun Wang Hao Wang Gaofeng Li Yuan Tang Chen Hu Wenyang Liu Hua Ren Shulian Wang Weihu Wang Yongwen Song Yueping Liu Hui Fang Yu Tang Ningning Lu Bo Chen Shunan Qi Yexiong Li Jing Jin 
supported by grants from Sanming Project of Medicine in Shenzhen(No.SZSM202211030);the Science and Technology Department Basic Research Project of Shanxi(No.202203021221284)。
Objective:Several studies have been conducted on the effects and toxicity of adding oxaliplatin to fluorouracilbased or capecitabine-based chemoradiotherapy(CRT)regimens as significantly increasing the toxic response ...
关键词：CHEMORADIOTHERAPY OXALIPLATIN CAPECITABINE rectal neoplasms drug therapy RADIOTHERAPY treatment outcome 
全选清除导出
共22页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部